Needling out Alzheimer’s

How AD vaccine UB-311 could be safer than other anti-beta amyloid therapies

United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding the adverse events associated with prior AD vaccines and mAbs against the same target.

The first clinically tested AD vaccine, AN-1792 from Elan Corp. plc and Wyeth (now part of Pfizer Inc.), was able to activate natural antibody production

Read the full 732 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE